Amgen Inc. · AMGN · Next earnings

Amgen Inc. reports Tuesday, Nov 3, 2026

AMGN reports after market close with consensus EPS at $5.79 and revenue at $10.05B. Last quarter: Amgen Beats Q1 Estimates, Raises 2026 Guidance as Growth Drivers Deliver

Reports After market close44 days awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $5.79 Calendar consensus
Consensus revenue $10.05B Calendar consensus
Report date Nov 3, 2026 Tuesday, date estimated
Session After market close 44 days away

Where AMGN left off: FY2026 Q1

Full report

Amgen Beats Q1 Estimates, Raises 2026 Guidance as Growth Drivers Deliver

EPS surprise +8.0% Reported $5.15 vs $4.77
Revenue surprise +0.5% Reported $8.62B vs $8.58B
Stock move -4.7% Event window
Subsequent drift -0.2% Up to 20 sessions

Management raised its full-year 2026 outlook: revenue to $37.1–$38.5 billion and EPS to $21.70–$23.10. Guidance sentiment was characterized as raised and management tone as confident. Capex is set at $2.6 billion, up from prior levels, reflecting investment in manufacturing capacity for forthcoming product launches. Prior-quarter guidance figures were not available for direct comparison.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • Patent expirations and biosimilar erosion, especially for Prolia and XGEVA.
  • Ongoing IRS tax litigation and potential adjustments for Puerto Rico allocations (2016–2018 tax years).
  • Regulatory uncertainties including potential FDA withdrawal of Tabneos for ANCA-associated vasculitis.
  • Clinical trial enrollment challenges and safety pauses, including blinatumomab.
  • Intensifying competition in the obesity and diabetes market from Novo Nordisk and Eli Lilly.

Questions analysts left open

  • Design specifics of Meritide switch study — dosing intervals and superiority versus non-inferiority design.
  • Imdeltra real-time trial design and FDA collaboration details.
  • Olpasiran trial considerations regarding background GLP-1 or PCSK9 therapies.
  • Blinatumomab enrollment pauses and subcutaneous development.
  • Dazodalibep Phase III trial strategy for systemic versus symptomatic Sjogren's disease.

Ask FN2 about AMGN next report

Transcript, numbers and history already loaded
What should I watch for in AMGN's next earnings report?How did AMGN guide last quarter, and is consensus above or below that?Give me the bull and bear case going into AMGN earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the AMGN recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent AMGN quarters

All AMGN earnings
-4.7%FY2026 Q1

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q1

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.